Austria as a pharmaceutical hub: framework conditions for efficient pharmaceutical production

An outlook by Christoph Reinwald, General Manager at Complex Pharmaceuticals.

Pharmaceutical production forms part of a complex value chain. Research, manufacturing, packaging, storage and distribution are all interlinked and work together to ensure the reliable supply of medicines to various markets.

Austria has well-established structures within the pharmaceutical industry, thereby providing a foundation for production and further processing stages within Europe. At the same time, the requirements placed on production sites are constantly changing. Energy efficiency, digitalisation, skilled labour, regulatory requirements and economic efficiency are increasingly influencing the development of modern production structures.

Site development amidst conflicting requirements

Pharmaceutical production sites must reconcile a wide range of requirements. High quality and safety standards necessitate, at the same time, efficient processes, a reliable infrastructure and production structures that can be planned for the long term.

For companies, this means continuously refining existing processes and making targeted use of technological opportunities. Automation, digital systems and flexible plant designs can help to make production processes more efficient and to accommodate different requirements within standardised quality processes.

The availability of qualified specialists and suitable infrastructure also plays a key role in this regard. Technological investments are particularly effective when the necessary specialist expertise and stable organisational structures are in place.

Site development as an integrated approach

The development of pharmaceutical production sites cannot be reduced to individual factors. Research, production, packaging, storage and logistics are closely interlinked and influence the performance of the entire value chain.

“An efficient production structure is created through the interplay of technology, skilled workers, efficient processes and reliable framework conditions.”

— Christoph Reinwald, General Manager at Complex Pharmaceuticals

From this perspective, the regional production infrastructure also gains in importance. Production and packaging capacities within Europe can help to shorten transport routes, reduce additional interfaces and make supply chains more flexible.

This is not about achieving complete independence from international supply chains. Rather, the focus is on how production structures can be sensibly diversified and complemented within Europe.

Technological development as an integral part of the location strategy

For companies, a key starting point lies in the further development of their own production structures.

At Complex Pharmaceuticals, this includes, amongst other things, modular packaging lines, automated processes and digital systems. Flexible plant designs enable the handling of different packaging formats and production volumes within defined GxP requirements.

This allows the technological and organisational conditions to be put in place to respond to different production programmes and changing requirements.

The interplay between infrastructure and framework conditions

The long-term development of a pharmaceutical location stems from the interplay of several factors. Companies can contribute to the further development of their production structures by investing in technology, processes and specialist expertise. At the same time, economic, regulatory and infrastructural framework conditions influence the circumstances under which such investments can be made.

For Austria and Europe, this means viewing location development as a long-term endeavour and bringing together the various requirements across the pharmaceutical value chain.

High-performance pharmaceutical production flourishes where technological infrastructure, specialist expertise, efficient processes and reliable framework conditions work together.